<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00986050</url>
  </required_header>
  <id_info>
    <org_study_id>CATHREINE-DEBATER 2006</org_study_id>
    <nct_id>NCT00986050</nct_id>
  </id_info>
  <brief_title>Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Elevation Myocardial Infarction</brief_title>
  <acronym>DEBATER</acronym>
  <official_title>A Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Segment Elevation Myocardial Infarction The Eindhoven Reperfusion Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catharina Ziekenhuis Eindhoven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Compusense Oegstgeest ( electronic randomization and CRF)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CATHREINE ( data monitoring)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Catharina Ziekenhuis Eindhoven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DEBATER study is designed to determine the superiority of abciximab over no abciximab and
      to determine the superiority of drug eluting stents over bare metal stents in patients with
      acute myocardial infarction who undergo percutaneous coronary intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with acute myocardial infarction primary PCI without prior thrombolytic therapy,
      is the treatment of choice.

      The recommendation for routine stenting in PCI is based on 4 studies that have demonstrated
      the usefulness of bare metal stents in patients with STEMI. However this recommendation
      cannot be extrapolated (yet) to the use of drug eluting stents. Although DES have been used
      widely in unstable angina and in acute myocardial infarction, to date there are no
      evidence-based recommendations to support the routine use of DES in STEMI.

      GPI have been studied extensively in patients with non-STsegment elevation myocardial
      infarctions (NSTEMI) with planned or performed PCI. In STEMI tirofiban and and eptifibatide
      are less well investigated, and only abciximab is recommended in primary PCI, but the long
      term benefits require more investigation. In PCI randomized controlled clinical trials
      (RCT's) abciximab consistently showed a significant reduction in the rate of myocardial
      infarction and the need for urgent revascularization. Abciximab has been evaluated in 5 RCT's
      in association with primary PCI. The pooled analysis for the clinical outcome at 30 days,
      demonstrate a significant reduction of death, re- infarction and target vessel
      revascularization (TVR), mainly due to a reduction of repeat intervention. The long-term
      benefits require more investigation.

      The DEBATER trial is designed to answer the questions about the need for abciximab and about
      the use of DES in primary PCI.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>target vessel failure</measure>
    <time_frame>30 days and one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac and cerebral adverse events ( MACCE)</measure>
    <time_frame>30 days and one year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">907</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Bare metal stent (BMS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug eluting stent (DES)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Abciximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No abciximab</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abciximab</intervention_name>
    <description>Abciximab bolus 0,25mg/kg, 10-60 minutes before PCI. Infusion 0,125ug/kg/min for 12 hours after PCI.</description>
    <arm_group_label>Abciximab</arm_group_label>
    <other_name>reopro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>bare metal stent prokinetic, chrono, skylor or bluemedical</intervention_name>
    <description>bare metal stent in culprit artery in acute myocardial infarction</description>
    <arm_group_label>Bare metal stent (BMS)</arm_group_label>
    <other_name>operator-dependent: prokinetic, chrono, skylor, bluemedical</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>drug eluting stent (sirolimus eluting) - CYPHER stent</intervention_name>
    <description>stent implantation in culprit artery in acute myocardial infarction</description>
    <arm_group_label>Drug eluting stent (DES)</arm_group_label>
    <other_name>CYPHER stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  STEMI ≤ 12 hours (or STEMI equivalent).

          -  No contra - indications for primary PCI.

          -  No contra - indications for abciximab.

          -  Informed consent from the patient.

        Exclusion Criteria:

          -  Contra - indication for primary PCI: History of peripheral/coronary artery disease
             that is inaccessible for angiography or PCI.

          -  Contra - indications for GPI: Ongoing bleeding, bleeding diathesis, cerebrovascular
             accident &lt; 6 months, major surgery/trauma &lt; 6 months, platelet count &lt; 100.000 mm3 ,
             intracranial arteriovenous malformation or neoplasm, malignant hypertension, INR &gt;1.5,
             severe hepatic dysfunction

          -  Contra - indications for clopidogrel:

               -  Severe liver dysfunction, pathological bleeding disorders such as peptic ulcer or
                  intracranial bleeding.

               -  Thrombolytic therapy &lt; 24 hours.

               -  Therapy with GPI &lt; 24 hours.

               -  Anticoagulation therapy.

          -  Co - morbid conditions with a predictable fatal outcome in the short run.

          -  No informed consent: refusal, coma, artificial respiration, impaired mentation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolf Michels</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catharina Ziekenhuis Eindhoven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Inge Wijnbergen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catharina Ziekenhuis Eindhoven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Catharina ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <state>Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm C, Jørgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W; Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005 Apr;26(8):804-47. Epub 2005 Mar 15.</citation>
    <PMID>15769784</PMID>
  </reference>
  <reference>
    <citation>Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc JM, Morice MC, Maillard L, Pansiéri M, Choussat R, Pinton P; ADMIRAL Investigators. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001 Jun 21;344(25):1895-903.</citation>
    <PMID>11419426</PMID>
  </reference>
  <reference>
    <citation>Schömig A, Schmitt C, Dibra A, Mehilli J, Volmer C, Schühlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ, Berger PB, Kastrati A; Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. Eur Heart J. 2005 Jul;26(14):1379-84. Epub 2005 Feb 25.</citation>
    <PMID>15734767</PMID>
  </reference>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2009</study_first_submitted>
  <study_first_submitted_qc>September 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2009</study_first_posted>
  <last_update_submitted>July 25, 2011</last_update_submitted>
  <last_update_submitted_qc>July 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2011</last_update_posted>
  <responsible_party>
    <name_title>Antoinette Spierings</name_title>
    <organization>CATHREINE</organization>
  </responsible_party>
  <keyword>STEMI</keyword>
  <keyword>DES</keyword>
  <keyword>BMS</keyword>
  <keyword>abciximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin Fab Fragments</mesh_term>
    <mesh_term>Abciximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

